Vardenafil (Levitra/Staxyn) vs Alprostadil (Caverject/MUSE): Head-to-Head Efficacy

How Each Drug Actually Works

Vardenafil and alprostadil both produce erections, but they target entirely different points in the penile vascular pathway. Understanding the mechanism gap explains why one succeeds where the other does not.

Vardenafil: Blocking PDE5 to Amplify cGMP

Vardenafil is a selective phosphodiesterase type-5 (PDE5) inhibitor. Sexual stimulation triggers nitric oxide (NO) release from cavernous endothelium, which raises cyclic guanosine monophosphate (cGMP) in smooth muscle cells. CGMP relaxes the trabecular smooth muscle, allowing blood to fill the corpus cavernosum. PDE5 normally breaks down cGMP and ends the erection. Vardenafil blocks PDE5, so cGMP accumulates and the erection persists [1].

The critical requirement: an intact NO-releasing pathway. Men with severe endothelial damage, radical prostatectomy nerve injury, or advanced diabetic neuropathy may produce insufficient NO, and vardenafil has little cGMP to amplify [2].

Alprostadil: Direct Smooth Muscle Relaxation via cAMP

Alprostadil is synthetic prostaglandin E1 (PGE1). It binds EP2/EP3 receptors on cavernous smooth muscle, activates adenylate cyclase, and raises cyclic adenosine monophosphate (cAMP) independently of NO [3]. CAMP relaxes smooth muscle through protein kinase A, inflating the corpus cavernosum without any neurogenic stimulus.

This NO-independence is the defining clinical advantage. A man whose nerve bundles were severed during prostatectomy can still achieve a pharmacologic erection from alprostadil [4]. That same property makes alprostadil the standard rescue agent after PDE5-inhibitor failure.

Vardenafil Efficacy: Trial Data

Vardenafil carries FDA approval for erectile dysfunction at doses of 5 mg, 10 mg, and 20 mg (Levitra film-coated tablets) and as a 10 mg orally disintegrating tablet (Staxyn) [5].

Diabetic ED: The Porst 2003 Data

Porst et al. (Int J Impot Res, 2003) studied vardenafil specifically in men with type 1 or type 2 diabetes, a population known for blunted PDE5-inhibitor response because of both neuropathy and endothelial dysfunction [6]. Vardenafil 10 mg and 20 mg produced statistically significant improvements on the International Index of Erectile Function (IIEF) erectile function domain compared with placebo (P<0.001 for both doses). The percentage of successful intercourse attempts rose from roughly 32% at baseline to 57% (10 mg) and 64% (20 mg), versus 36% for placebo [6].

These numbers are meaningful: even in a mechanistically disadvantaged group, vardenafil nearly doubled the success rate compared with placebo.

Broad Efficacy Across ED Etiologies

A pooled analysis of three phase III trials (N=2,431) published in the journal Urology reported that vardenafil 20 mg achieved erections firm enough for intercourse in approximately 80% of attempts, versus 52% with placebo [7]. The FDA label summarizes consistent IIEF domain score improvements of 6 to 8 points above placebo across all severity strata [5].

Staxyn vs. Levitra Bioavailability

The orally disintegrating Staxyn formulation produces roughly 21% higher peak plasma concentrations (Cmax) compared with the film-coated Levitra tablet at the same 10 mg dose [5]. This pharmacokinetic difference means the two formulations are not dose-substitutable; Staxyn 10 mg is not bioequivalent to Levitra 10 mg for regulatory purposes [5].

Alprostadil Efficacy: Trial Data

Alprostadil is available as intracavernosal injection (Caverject, Edex) at 5 to 40 mcg per dose, and as an intraurethral suppository (MUSE) at 125 to 1,000 mcg [8].

PDE5-Failure Refractory ED: The Linet 1996 NEJM Trial

Linet and Ogrinc (N Engl J Med, 1996) published a landmark placebo-controlled trial of intracavernosal alprostadil in 683 men with erectile dysfunction of broad etiology, many of whom had not responded to other treatments [9]. At the highest tested dose (20 mcg), approximately 70% of injections produced an erection sufficient for intercourse, compared with 11% in the placebo group (P<0.001) [9].

This 70% figure in a refractory cohort is frequently cited as the reason alprostadil remains a frontline option after oral agent failure. The number matters: most PDE5 inhibitors lose their effectiveness in this same population, yet alprostadil retained significant activity [9].

MUSE vs. Caverject: Intraurethral vs. Intracavernosal

Intraurethral MUSE is substantially less effective than intracavernosal Caverject. A controlled study found in-clinic response rates of about 65% for ICI alprostadil versus 43% for MUSE at home [10]. The MUSE mechanism requires passive absorption across the urethral mucosa into the corpus spongiosum and then diffusion into the corpus cavernosum, a less direct route that reduces bioavailability [8].

MUSE carries a convenience advantage for needle-averse patients, but the efficacy trade-off is real.

Alprostadil in Post-Prostatectomy ED

Radical prostatectomy severs or injures the cavernous nerves in a high proportion of cases, even with nerve-sparing technique. Because alprostadil bypasses nerve-mediated NO release entirely, it retains erection-inducing capacity in this population. Published series report ICI alprostadil response rates of 60 to 85% in post-prostatectomy men, depending on nerve-sparing status [4]. The American Urological Association (AUA) guideline on ED acknowledges ICI therapy as appropriate second-line treatment after nerve-sparing prostatectomy [11].

Side-Effect and Safety Profiles

The tolerability gap between these two agents is wide and directly affects long-term adherence.

Vardenafil Safety

Common adverse effects from the FDA label include headache (15%), flushing (11%), rhinitis (9%), and dyspepsia (4%) [5]. Hypotension is the primary serious concern. Vardenafil is absolutely contraindicated with all nitrate formulations (nitroglycerin, isosorbide mononitrate/dinitrate) and with soluble guanylate cyclase stimulators (riociguat) because the combination can produce severe, potentially fatal blood pressure drops [5].

QTc prolongation is a class concern. Vardenafil prolongs the QT interval more than sildenafil or tadalafil at comparable doses, and co-administration with Class IA or III antiarrhythmics is contraindicated [5].

Alprostadil Safety

The dominant adverse effect of ICI alprostadil is penile pain, reported in 30 to 50% of injections in clinical trials [9]. Prolonged erection (priapism) lasting more than 4 hours occurs in approximately 1 to 2% of doses and constitutes a urological emergency requiring aspiration or sympathomimetic injection [8].

MUSE carries a lower priapism risk but causes urethral burning in up to 36% of users and systemic hypotension in about 3%, partly because PGE1 is a vasodilator with systemic absorption potential [10].

Alprostadil has no interaction with nitrates. This is a critical safety distinction for men who take nitrates for coronary artery disease and cannot use any PDE5 inhibitor.

Comparative Efficacy: What the Evidence Actually Shows

No published randomized controlled trial has compared vardenafil directly against alprostadil in the same blinded study. Synthesizing across trial populations is the only evidence-based approach currently available.

The table below maps the best available data to clinical scenarios. Response rates come from the primary trials cited in this article and should be interpreted in the context of each trial's population.

| Clinical Scenario | Vardenafil Best Estimate | Alprostadil ICI Best Estimate | Preferred Agent | |---|---|---|---| | Broad ED population, no prior treatment | ~80% intercourse success [7] | ~70 to 80% per injection [9] | Vardenafil (oral, fewer local AEs) | | Diabetic ED | ~57 to 64% intercourse success [6] | ~60 to 70% (extrapolated) [9] | Vardenafil first; ICI if failure | | Post-radical prostatectomy ED | ~35 to 50% (nerve injury limits NO) [2] | ~60 to 85% [4] | Alprostadil ICI | | PDE5-inhibitor refractory ED | Not applicable | ~70% [9] | Alprostadil ICI | | Nitrate co-medication | Contraindicated [5] | Safe to use [8] | Alprostadil only | | Needle-averse patient | Preferred | MUSE (~43% home response) [10] | Vardenafil first; MUSE if ICI refused |

The pattern is consistent across sources: vardenafil is the rational first-line oral option for most men because it is effective, non-invasive, and well-studied. Alprostadil moves to the front when nerve damage disrupts the NO pathway, when PDE5 inhibitors have already failed, or when nitrate co-medication makes PDE5 inhibitors unsafe.

Dosing and Administration

Vardenafil Dosing

• Levitra: start at 10 mg taken 60 minutes before sexual activity; titrate to 5 mg or 20 mg based on response and tolerability [5].
• Staxyn: 10 mg orally disintegrating tablet, not to be substituted milligram-for-milligram for Levitra [5].
• Maximum frequency: once per 24 hours [5].
• High-fat meals reduce absorption and delay onset; a light meal or fasted state is preferred [5].
• Alpha-blocker co-use requires a minimum 6-hour interval between doses to reduce orthostatic hypotension risk [5].

Alprostadil Dosing

• Caverject (ICI): titration starts at 2.5 mcg in neurogenic ED or 5 mcg in vasculogenic ED; dose increases in 2.5 to 5 mcg steps until the lowest effective dose producing a 60-minute erection is identified [8]. Maximum single dose is 40 mcg.
• MUSE: available at 125, 250, 500, and 1,000 mcg; titration performed in-office to identify the effective dose before home use [8].
• Frequency limit: ICI alprostadil should not be used more than 3 times per week, with at least 24 hours between doses [8].
• First-dose titration for Caverject must occur in a clinical setting because of priapism risk [8].

Who Should Use Which Drug: A Clinical Decision Framework

The AUA guideline (2018, amended 2022) places PDE5 inhibitors as first-line pharmacotherapy for ED in most men, with ICI therapy as second-line after oral agent failure or contraindication [11]. The Endocrine Society clinical practice guideline on male sexual dysfunction notes that PDE5 inhibitors are appropriate first-line agents unless specific contraindications exist [12].

Specific situations where alprostadil should come first or should replace vardenafil:

1. Post-radical prostatectomy with bilateral nerve sacrifice. Cavernous nerve integrity is required for PDE5-inhibitor action. Alprostadil ICI works independently [4].
2. Nitrate use for cardiovascular disease. All PDE5 inhibitors are contraindicated; alprostadil carries no nitrate interaction and is the only pharmacologic erection therapy available [5][8].
3. Documented PDE5-inhibitor failure after adequate trial. A fair trial means at least four attempts at the maximum tolerated dose with adequate sexual stimulation. Once that threshold is met, alprostadil ICI at a titrated dose achieves erections in roughly 70% of cases [9].
4. Severe arterial insufficiency. When penile arterial disease is so severe that even maximally elevated cGMP cannot produce sufficient inflow, bypassing the NO system entirely via cAMP may produce better results [3].

Specific situations where vardenafil should come first:

1. No prior PDE5-inhibitor trial. Start with the least invasive, most tolerable option [11].
2. Psychogenic or mixed-etiology ED with preserved endothelial function. NO signaling is intact; amplifying it is sufficient [2].
3. Needle phobia or partner-discomfort with injection. Adherence to ICI is poor in this group, and poor adherence negates any efficacy advantage [13].
4. Younger men with diabetes who retain partial nerve function. Porst 2003 showed meaningful benefit even in this compromised group [6].

Combination Therapy

Some men respond better to both agents together than to either alone. Low-dose ICI alprostadil combined with an oral PDE5 inhibitor may produce additive smooth muscle relaxation via simultaneous cAMP and cGMP elevation [14]. A prospective series reported that combination therapy salvaged erections in approximately 50% of men who failed maximal-dose PDE5 inhibitor monotherapy and had suboptimal ICI response [14].

Combination use requires careful dose titration to avoid priapism. Neither agent should be at maximum dose when combined. This approach should be managed by a urologist or sexual medicine specialist [11].

Switching Between Agents

Men switching from vardenafil to alprostadil, or vice versa, should expect a formal re-titration period for alprostadil. Because ICI dose-response varies substantially between individuals, the first alprostadil dose must be administered in a clinical setting [8]. Vardenafil can be self-initiated at home after a physician prescribes the starting dose, making re-initiation simpler [5].

The AUA recommends that clinicians reassess erectile function with a validated tool such as the IIEF-5 (Sexual Health Inventory for Men) at each switch point to document whether the new agent is actually performing better for that patient [11].

Penile rehabilitation after prostatectomy frequently involves a sequential algorithm: oral PDE5 inhibitors nightly for oxygenation of cavernous tissue, then ICI alprostadil on an as-needed basis once the patient is ready for intercourse attempts. The two agents serve different functions in this protocol rather than competing directly [4].

Cost and Access Considerations

Generic vardenafil tablets became widely available after 2018 patent expiration. A 30-tablet supply of generic vardenafil 10 mg averages $40, $90 at most U.S. Pharmacies [15]. Brand Levitra and Staxyn cost substantially more and are rarely covered without step-therapy failure of generic PDE5 inhibitors [15].

Generic alprostadil ICI (Prostin VR reformulated for ICI) costs roughly $25, $60 per single-use vial at compounding pharmacies; brand Caverject Impulse retails at $80, $150 per vial [15]. MUSE suppositories range from $70, $130 per dose without insurance coverage [15].

Over a typical month of 4 to 8 sexual encounters, ICI alprostadil costs 3 to 6 times more than oral generic vardenafil on a per-use basis. Cost is not a trivial factor in long-term adherence.

Patient Adherence and Satisfaction

Long-term adherence data favor oral agents. A prospective study following men for 24 months found that approximately 40% of ICI alprostadil users discontinued therapy within the first year, with penile pain and injection anxiety as the leading reasons [13]. By comparison, PDE5-inhibitor discontinuation at 12 months is lower, ranging from 25 to 35% across published series, with lack of efficacy rather than tolerability as the primary driver [16].

Patient satisfaction scores on validated measures such as the Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) tend to be higher for oral agents when efficacy is comparable [16]. When ICI alprostadil is the only effective option, satisfaction scores are high despite the invasiveness, because a working erection is preferred over no erection [9].

Partner satisfaction data are sparse but generally parallel patient-reported outcomes [16].

Summary of Key Differences

| Feature | Vardenafil (Levitra/Staxyn) | Alprostadil (Caverject/MUSE) | |---|---|---| | Route | Oral | ICI or intraurethral | | Mechanism | PDE5 inhibition, cGMP amplification | EP receptor agonism, cAMP elevation | | Requires sexual stimulation | Yes | No | | Efficacy in broad ED | ~80% [7] | ~70 to 80% ICI [9] | | Efficacy post-prostatectomy | ~35 to 50% [2] | ~60 to 85% ICI [4] | | PDE5-failure refractory | Not applicable | ~70% [9] | | Nitrate interaction | Contraindicated [5] | None [8] | | Main adverse effect | Headache, flushing [5] | Penile pain 30 to 50% [9] | | Priapism risk | <0.1% | 1 to 2% ICI [8] | | Adherence at 12 months | ~65 to 75% [16] | ~60% ICI [13] |